Elsevier

Phytomedicine

Volume 102, 20 July 2022, 154166
Phytomedicine

Effect of Qingfei Paidu decoction combined with Western medicine treatments for COVID-19: A systematic review and meta-analysis

https://doi.org/10.1016/j.phymed.2022.154166Get rights and content
Under a Creative Commons license
open access

Abstract

Background

Qingfei Paidu decoction (QFPDD) showed to be beneficial for the treatment of coronavirus disease 2019 (COVID-19) in China.

Purpose

This study aimed to systematically assemble the evidence on the efficacy and safety of QFPDD combined with Western medicine treatments (WMT) for COVID-19.

Study design

Systematic review and meta-analysis.

Methods

A comprehensive literature search was conducted in PubMed, Embase, Cochrane Library, CNKI, CSTJ, CBM, Wanfang Data for clinical trials with a control arm until January 13, 2022. Studies matched the selection criteria were included. Data extraction and quality assessment of the included studies were independently conducted by two reviewers. Review Manager 5.4 was used for meta-analysis.

Results

A total of 9 trials including 1108 COVID-19 patients met the selection criteria. Meta-analysis demonstrated that QFPDD combined with WMT reduced aggravation rate (AR) by 71% [risk ratio (RR) = 0.29, 95% confidence intervals (CI) (0.17, 0.51)], increased effective rate (ER) by 13% [RR = 1.13, 95%CI (1.04, 1.22)], shortened 4.78 days of viral shedding [95%CI (-5.79, -3.77)] and 4.45 days of hospital stay [95%CI (-6.05, -2.86)], also decreased the incidence of adverse events (AE) by 56% [RR = 0.44, 95%CI (0.22, 0.89)].

Conclusion

QFPDD combined with WMT might reduce the proportion of severe cases and the incidence of AE, shorten the duration of viral shedding and length of hospital stay. More randomized controlled trials (RCTs) are required to confirm our findings in the future.

Keywords

Qingfei Paidu decoction
COVID-19
Western medicine treatments
Clinical effect
Systematic review
Meta-analysis

Abbreviations

AE
adverse events
AR
aggravation rate
CBM
China Biology Medicine
CI
confidence intervals
CNKI
China National Knowledge Infrastructure
COVID-19
coronavirus disease 2019
CSTJ
China Science and Technology Journal Database
ER
effective rate
MD
mean difference
MINORS
methodological index for non-randomized studies
NHC
the National Health Commission
non-RCTs
non-randomized concurrent trials
RR
risk ratio
PRISMA
the Preferred Reporting Items for Systematic Reviews and Meta-analyses
QFPDD
Qingfei Paidu decoction
RCTs
randomized controlled trials
SATCM
the State Administration of Traditional Chinese Medicine
TCM
traditional Chinese medicine
WMT
Western medicine treatments

Cited by (0)

1

These authors contributed equally to this work